RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @TiansterZhang: Excellent molecular profiling of #bladdercancer - FGFR genomic alterations exclusive of TP53 alterations. TP53 changes u…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
RT @VivekSubbiah: ⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Out…
⭐️Our paper👉Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR_AACR is a follow up to @neerajaiims @montypal @PGrivasMDPhD's paper on NGS in Bladder cancer @OncHahn @oalhalabimd https://
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @TiansterZhang: Excellent molecular profiling of #bladdercancer - FGFR genomic alterations exclusive of TP53 alterations. TP53 changes u…
RT @TiansterZhang: Excellent molecular profiling of #bladdercancer - FGFR genomic alterations exclusive of TP53 alterations. TP53 changes u…
RT @TiansterZhang: Excellent molecular profiling of #bladdercancer - FGFR genomic alterations exclusive of TP53 alterations. TP53 changes u…
Excellent molecular profiling of #bladdercancer - FGFR genomic alterations exclusive of TP53 alterations. TP53 changes unfortunately the worst for prognosis. We have still much to do to improve outcomes in #bladdercancer. @BladderCancerUS @mouwlab @FaltasL
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
RT @VivekSubbiah: ⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR…
⭐️Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @MCR_AACR @AACR @oalhalabimd @PavlosMsaouel @OncHahn @OncoAlert https://t.co/rJx1mHYccc https://t.co/AhYQjtNp0R
Patients with metastatic #BladderCarcinoma and a targetable alteration may derive clinical benefit from participating in early phase trials involving targeted therapy, but patients with TP53-alt need innovative therapies. @MDAndersonNews #RapidImpact htt
RT @oalhalabimd: 1/🌟 Excited to share our brief paper with @OncHahn @PavlosMsaouel @JasonRoszik and @MDAndersonNews team, looking at patien…
RT @oalhalabimd: 1/🌟 Excited to share our brief paper with @OncHahn @PavlosMsaouel @JasonRoszik and @MDAndersonNews team, looking at patien…
👏👏nice work @MDACC team!! despite being a retrospective study show 2 relevant results: 📌 a poor prognostic of platinum-refractory pts in real-world! (mOS 9.6 mo)without ICI efficacy? 📌98% pts harbored 1 som alt:TP53, ERBB2, PI3KCA, FGFR3, ARID1A (66%, 29%,
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
RT @VivekSubbiah: ⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉…
⭐️🚨 Thrilled to share our Rapid Impact paper from @MCR_AACR from @oalhalabimd @OncHahn @PavlosMsaouel et al dream team 👉 Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @OncoAlert https:/
RT @VivekSubbiah: 🚨Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @oalh…
RT @VivekSubbiah: 🚨Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @oalh…
RT @VivekSubbiah: 🚨Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @oalh…
RT @VivekSubbiah: 🚨Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @oalh…
🚨Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes @oalhalabimd @OncHahn @PavlosMsaouel https://t.co/rJx1mHYccc
Patients with metastatic #BladderCarcinoma and a targetable alteration may derive clinical benefit from participating in early phase trials involving targeted therapy, but patients with TP53-alt need innovative therapies. @MDAndersonNews #RapidImpact htt
RT @TomSilver39: Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes https:/…
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes https://t.co/wDEwgsyDHf https://t.co/H6ftMlfM4p
@MonikaJoshimd @PGrivasMDPhD @ERPlimackMD @TiansterZhang @SheldonLHolder @ZakhariaYousef @shilpaonc @tompowles1 @DrRosenbergMSK @neerajaiims @montypal @PatrickCMa1 Rare indeed, one out of 43 metastatic UC patients referred to our phase I group had BRAF mis
RT @oalhalabimd: Our rapid impact paper on precision medicine in bladder cancer with @VivekSubbiah @PavlosMsaouel @OncHahn @JasonRoszik and…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @OncoAlert: Day1⃣ #GU21 #OncoAlertTopTweet 🚨by @VivekSubbiah Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Partici…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 5/6 Among patients with urothelial carcinoma histology, those harboring a TP53 alteration had a shorter mPFS vs those who…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @oalhalabimd: Our rapid impact paper on precision medicine in bladder cancer with @VivekSubbiah @PavlosMsaouel @OncHahn @JasonRoszik and…
RT @oalhalabimd: Our rapid impact paper on precision medicine in bladder cancer with @VivekSubbiah @PavlosMsaouel @OncHahn @JasonRoszik and…
RT @oalhalabimd: Our rapid impact paper on precision medicine in bladder cancer with @VivekSubbiah @PavlosMsaouel @OncHahn @JasonRoszik and…
Our rapid impact paper on precision medicine in bladder cancer with @VivekSubbiah @PavlosMsaouel @OncHahn @JasonRoszik and other awesome collaborators @MDAndersonNews. Targeting FGFR seemed to work. Other alterations are waiting to be targeted ⚽️🥅
RT @oncologician: 📣Excellent thread on Precision oncology in Urothelial ca 🎯🧬 https://t.co/WT6fb0tpnH
RT @montypal: OMG @neerajaiims @TiansterZhang @DrChoueiri - we have finally succeeded in our mission to turn @VivekSubbiah into a GU medica…
RT @OncoAlert: Day1⃣ #GU21 #OncoAlertTopTweet 🚨by @VivekSubbiah Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Partici…
RT @VivekSubbiah: 🚨🥁 Just in time for #GU21 @ASCO 👉 Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts…
RT @VivekSubbiah: 5/6 Among patients with urothelial carcinoma histology, those harboring a TP53 alteration had a shorter mPFS vs those who…
RT @VivekSubbiah: 6/6 Implications: Patients with platinum-refractory mBC derive clinical benefit from participating in early-phase clinica…
RT @OncoAlert: Day1⃣ #GU21 #OncoAlertTopTweet 🚨by @VivekSubbiah Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Partici…
RT @OncoAlert: Day1⃣ #GU21 #OncoAlertTopTweet 🚨by @VivekSubbiah Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Partici…
RT @OncoAlert: Day1⃣ #GU21 #OncoAlertTopTweet 🚨by @VivekSubbiah Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Partici…
RT @montypal: OMG @neerajaiims @TiansterZhang @DrChoueiri - we have finally succeeded in our mission to turn @VivekSubbiah into a GU medica…
RT @VJOncology: See our #ASCOGU page for #BladderCancer updates! 👉https://t.co/VCR0x3rgeE👈 #GU21 @ASCO @OncoAlert @ASTRO_org #UroSoMe #Ur…